United States v. Glaxo Group Ltd.
| United States v. Glaxo Group Ltd. | |
|---|---|
| Argued November 9, 1972 Decided January 22, 1973 | |
| Full case name | United States v. Glaxo Group Ltd. |
| Citations | 410 U.S. 52 (more) 93 S. Ct. 861; 35 L. Ed. 2d 104; 1973 U.S. LEXIS 26; 176 U.S.P.Q. (BNA) 289; 1973 Trade Cas. (CCH) ¶ 74,323 |
| Case history | |
| Prior | 328 F. Supp. 709 (D.D.C. 1971); probable jurisdiction noted, 405 U.S. 914 (1972). |
| Holding | |
| When a patent is directly involved in an antitrust violation, the Government may challenge the validity of the patent. | |
| Court membership | |
| |
| Case opinions | |
| Majority | White, joined by Burger, Douglas, Brennan, Marshall, Powell |
| Dissent | Rehnquist, joined by Stewart and Blackmun |
| Laws applied | |
| Sherman Act | |
United States v. Glaxo Group Ltd., 410 U.S. 52 (1973), is a 1973 decision of the United States Supreme Court in which the Court held that (1) when a patent is directly involved in an antitrust violation, the Government may challenge the validity of the patent; and (2) ordinarily, in patent-antitrust cases, "[m]andatory selling on specified terms and compulsory patent licensing at reasonable charges are recognized antitrust remedies."